These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 36507829)

  • 41. Evaluation of NAFLD and fibrosis in obese patients - a comparison of histological and clinical scoring systems.
    Schmitz SM; Kroh A; Ulmer TF; Andruszkow J; Luedde T; Brozat JF; Neumann UP; Alizai PH
    BMC Gastroenterol; 2020 Aug; 20(1):254. PubMed ID: 32758151
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Application of Fatty Liver Inhibition of Progression Algorithm and Steatosis, Activity, and Fibrosis Score to Assess the Impact of Non-Alcoholic Fatty Liver on Untreated Chronic Hepatitis B Patients.
    Huang Y; Gan Q; Lai R; Wang W; Guo S; Sheng Z; Chen L; Guo Q; Cai W; Wang H; Zhao G; Cao Z; Xie Q
    Front Cell Infect Microbiol; 2021; 11():733348. PubMed ID: 35111690
    [TBL] [Abstract][Full Text] [Related]  

  • 43. (
    Molina-Molina E; Shanmugam H; Di Ciaula A; Grattagliano I; Di Palo DM; Palmieri VO; Portincasa P
    JHEP Rep; 2021 Feb; 3(1):100203. PubMed ID: 33490935
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Temporary kidney dysfunction: Robuvit® supplementation in initial, transient kidney insufficiency and micro-macro albuminuria.
    Ledda A; Belcaro G; Feragalli B; Hosoi M; Cacchio M; Luzzi R; Dugall M; Cotellese R; Cesarone MR
    Panminerva Med; 2018 Jun; 60(2):60-64. PubMed ID: 29737149
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Non-alcoholic fatty liver disease (NAFLD) and significant hepatic fibrosis defined by non-invasive assessment in patients with type 2 diabetes.
    Sobhonslidsuk A; Pulsombat A; Kaewdoung P; Petraksa S
    Asian Pac J Cancer Prev; 2015; 16(5):1789-94. PubMed ID: 25773826
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease.
    Angulo P; Bugianesi E; Bjornsson ES; Charatcharoenwitthaya P; Mills PR; Barrera F; Haflidadottir S; Day CP; George J
    Gastroenterology; 2013 Oct; 145(4):782-9.e4. PubMed ID: 23860502
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Accuracy of Noninvasive Fibrosis Scores to Detect Advanced Fibrosis in Patients With Type-2 Diabetes With Biopsy-proven Nonalcoholic Fatty Liver Disease.
    Singh A; Gosai F; Siddiqui MT; Gupta M; Lopez R; Lawitz E; Poordad F; Carey W; McCullough A; Alkhouri N
    J Clin Gastroenterol; 2020; 54(10):891-897. PubMed ID: 32168133
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Screening for non-alcoholic fatty liver disease in type 2 diabetes using non-invasive scores and association with diabetic complications.
    Ciardullo S; Muraca E; Perra S; Bianconi E; Zerbini F; Oltolini A; Cannistraci R; Parmeggiani P; Manzoni G; Gastaldelli A; Lattuada G; Perseghin G
    BMJ Open Diabetes Res Care; 2020 Feb; 8(1):. PubMed ID: 32049637
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The Effect of Probiotics (MCP
    Mohamad Nor MH; Ayob N; Mokhtar NM; Raja Ali RA; Tan GC; Wong Z; Shafiee NH; Wong YP; Mustangin M; Nawawi KNM
    Nutrients; 2021 Sep; 13(9):. PubMed ID: 34579068
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinical profile of non-alcoholic fatty liver disease in nonobese patients.
    Lum JHM; Cheah MCC; Leow WQ; Wan WK; Lim TKH; Chow WC; Chang JPE; Goh GBB
    J Gastroenterol Hepatol; 2021 Jan; 36(1):257-261. PubMed ID: 32557741
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Oral coenzyme Q10 supplementation in patients with nonalcoholic fatty liver disease: effects on serum vaspin, chemerin, pentraxin 3, insulin resistance and oxidative stress.
    Farhangi MA; Alipour B; Jafarvand E; Khoshbaten M
    Arch Med Res; 2014 Oct; 45(7):589-95. PubMed ID: 25450583
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Use of non-invasive parameters of non-alcoholic steatohepatitis and liver fibrosis in daily practice--an exploratory case-control study.
    Dvorak K; Stritesky J; Petrtyl J; Vitek L; Sroubkova R; Lenicek M; Smid V; Haluzik M; Bruha R
    PLoS One; 2014; 9(10):e111551. PubMed ID: 25350286
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The Fatty Liver Assessment in Germany (FLAG) cohort study identifies large heterogeneity in NAFLD care.
    Hofmann WP; Buggisch P; Schubert L; Dikopoulos N; Schwenzer J; Muche M; Felten G; Heyne R; Ingiliz P; Schmidt A; Stein K; Wedemeyer H; Berg T; Wiegand J; Lammert F; Zeuzem S; Schattenberg JM
    JHEP Rep; 2020 Dec; 2(6):100168. PubMed ID: 32964201
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The Association between Non-Alcoholic Fatty Liver Disease (NAFLD) and Advanced Fibrosis with Serological Vitamin B12 Markers: Results from the NHANES 1999-2004.
    Li L; Huang Q; Yang L; Zhang R; Gao L; Han X; Ji L; Zou X
    Nutrients; 2022 Mar; 14(6):. PubMed ID: 35334881
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Vitamin D and nonalcoholic fatty liver disease in children: a randomized controlled clinical trial.
    El Amrousy D; Abdelhai D; Shawky D
    Eur J Pediatr; 2022 Feb; 181(2):579-586. PubMed ID: 34459959
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice.
    Ganz M; Bukong TN; Csak T; Saha B; Park JK; Ambade A; Kodys K; Szabo G
    J Transl Med; 2015 Jun; 13():193. PubMed ID: 26077675
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Diagnostic Accuracy of Noninvasive Fibrosis Models to Detect Change in Fibrosis Stage.
    Siddiqui MS; Yamada G; Vuppalanchi R; Van Natta M; Loomba R; Guy C; Brandman D; Tonascia J; Chalasani N; Neuschwander-Tetri B; Sanyal AJ;
    Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1877-1885.e5. PubMed ID: 30616027
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Omega-3 fatty acids as a treatment for non-alcoholic fatty liver disease in children: A systematic review and meta-analysis of randomized controlled trials.
    Chen LH; Wang YF; Xu QH; Chen SS
    Clin Nutr; 2018 Apr; 37(2):516-521. PubMed ID: 28040302
    [TBL] [Abstract][Full Text] [Related]  

  • 59. AST to Platelet Ratio Index and fibrosis 4 calculator scores for non-invasive assessment of hepatic fibrosis in patients with non-alcoholic fatty liver disease.
    Peleg N; Issachar A; Sneh-Arbib O; Shlomai A
    Dig Liver Dis; 2017 Oct; 49(10):1133-1138. PubMed ID: 28572039
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Factors predicting non-alcoholic steatohepatitis (NASH) and advanced fibrosis in patients with non-alcoholic fatty liver disease (NAFLD).
    Tasneem AA; Luck NH; Majid Z
    Trop Doct; 2018 Apr; 48(2):107-112. PubMed ID: 29145775
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.